TEV-56278

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameTEV-56278
Drug Alias NameTEV-56278
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnti-PD-1Anti-Interleukin-2
TargetsProgrammed cell death protein 1Interleukin-2
Therapy Area/IndicationsSolid tumoursMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesIsrael
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTeva Pharmaceutical Industries Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Fosun Pharmaceutical (Group) Co LtdTeva Branded Pharmaceutical Products R&D LLCTeva Pharmaceutical Industries Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursMelanomaNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A